Compare UDMY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | GLUE |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2021 |
| Metric | UDMY | GLUE |
|---|---|---|
| Price | $5.80 | $16.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $9.00 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 4.1M | 1.2M |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $795,801,000.00 | $181,538,000.00 |
| Revenue This Year | $2.34 | $81.52 |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | ★ N/A | $64.14 |
| Revenue Growth | 2.53 | ★ 1112.27 |
| 52 Week Low | $4.86 | $3.50 |
| 52 Week High | $10.61 | $19.17 |
| Indicator | UDMY | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 54.50 |
| Support Level | $5.80 | $14.97 |
| Resistance Level | $7.16 | $19.17 |
| Average True Range (ATR) | 0.32 | 1.24 |
| MACD | 0.10 | -0.30 |
| Stochastic Oscillator | 34.95 | 41.28 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.